hit counter
Capricor Therapeutics, Inc. (CAPR) Stock News Sentiment & Price - Sentifly
CAPR - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Capricor Therapeutics, Inc. (CAPR)

USA
Biotechnology
NASDAQ
CAPR Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CAPR Latest news
Benzinga
Positive
Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%
2021-09-24 09:28

Capricor Therapeutics Inc (NASDAQ: CAPR) has announced final data from Phase 2 HOPE-2 trial of CAP-1002 for advanced stages of Duchenne muscular dystrophy (DMD).  The trial met its primary efficacy endpoint of mid-level performance of upper limb (mid-PUL v1.2) and various skeletal and cardiac function endpoints.

Pulse2
Positive
CAPR Stock: Why It Substantially Increased Today
2021-09-24 07:25

The stock price of Capricor Therapeutics Inc (NASDAQ: CAPR) increased by over 17% pre-market. This is why it happened.

GlobeNewsWire
Neutral
Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
2021-09-24 07:00

–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)–

GlobeNewsWire
Neutral
Capricor Therapeutics to Present at the Upcoming Investor and Industry Healthcare Conferences
2021-09-22 16:05

-  Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 -

PennyStocks
Positive
Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts
2021-09-19 10:25

Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?

GlobeNewsWire
Neutral
Capricor Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
2021-09-07 09:00

-Conference Dates: September 13–15, 2021- -Conference Dates: September 13–15, 2021-

GlobeNewsWire
Neutral
Capricor Therapeutics to Present Final Data from HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society 2021
2021-09-02 08:30

-Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Presentation, One of Only Three Selected by WMS- -Principal Investigator Dr. Craig McDonald Will Deliver Late-Breaking Oral Presentation, One of Only Three Selected by WMS-

Seeking Alpha
Neutral
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2021 Results - Earnings Call Transcript
2021-08-12 23:14

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
Capricor Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-08-12 16:01

CAP-1002 – Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase III Trial Protocol Submitted to FDA Following FDA Guidance--Commencing Start-Up Activities for Pivotal Trial--Phase II, HOPE-2 Final Data Submitted for Publication-

GlobeNewsWire
Neutral
Capricor Therapeutics to Present Second Quarter 2021 Financial Results and Recent Corporate Update on August 12
2021-08-05 09:00

Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET Company to Host Conference Call, August 12, 2021, at 4:30 p.m. ET

Loading more news...